#ebolaviruses

[eduebookstore]

Ebolaviruses: Methods and Protocols by Thomas Hoenen, ISBN-13: 978-1493971152 [PDF eBook eTextbook] Publisher: ‎ Humana; 1st ed. 2017 edition (June 1, 2017) Language: ‎ English 413 pages ISBN-10: ‎ 1493971158 ISBN-13: ‎ 978-1493971152 This vital book collects key methods that have supported advancements in the field of ebolavirus molecular biology given the pressing need for the advancement of techniques for diagnostics, the development of vaccines and antivirals, and for furthering our understanding of ebolavirus biology. After an introduction, the volume delves into protocols for studying ebolavirus molecular biology under biosafety level 2 conditions, studying infectious ebolaviruses under biosafety level 4 conditions in vitro as well as in vivo, and working with ebolaviruses in the field. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Ebolaviruses: Methods and Protocols serves as a guide to the next generations of filovirus researchers and also helps to bring experts from other areas into the filovirus research arena. What makes us different? • Instant Download • Always Competitive Pricing • 100% Privacy • FREE Sample Available • 24-7 LIVE Customer Support

[instantebookmart]

Ebolaviruses: Methods and Protocols by Thomas Hoenen, ISBN-13: 978-1493971152 [PDF eBook eTextbook] Publisher: ‎ Humana; 1st ed. 2017 edition (June 1, 2017) Language: ‎ English 413 pages ISBN-10: ‎ 1493971158 ISBN-13: ‎ 978-1493971152 This vital book collects key methods that have supported advancements in the field of ebolavirus molecular biology given the pressing need for the advancement of techniques for diagnostics, the development of vaccines and antivirals, and for furthering our understanding of ebolavirus biology. After an introduction, the volume delves into protocols for studying ebolavirus molecular biology under biosafety level 2 conditions, studying infectious ebolaviruses under biosafety level 4 conditions in vitro as well as in vivo, and working with ebolaviruses in the field. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Ebolaviruses: Methods and Protocols serves as a guide to the next generations of filovirus researchers and also helps to bring experts from other areas into the filovirus research arena. What makes us different? • Instant Download • Always Competitive Pricing • 100% Privacy • FREE Sample Available • 24-7 LIVE Customer Support

[royalebook]

Ebolaviruses: Methods and Protocols by Thomas Hoenen, ISBN-13: 978-1493971152 [PDF eBook eTextbook] Publisher: ‎ Humana; 1st ed. 2017 edition (June 1, 2017) Language: ‎ English 413 pages ISBN-10: ‎ 1493971158 ISBN-13: ‎ 978-1493971152 This vital book collects key methods that have supported advancements in the field of ebolavirus molecular biology given the pressing need for the advancement of techniques for diagnostics, the development of vaccines and antivirals, and for furthering our understanding of ebolavirus biology. After an introduction, the volume delves into protocols for studying ebolavirus molecular biology under biosafety level 2 conditions, studying infectious ebolaviruses under biosafety level 4 conditions in vitro as well as in vivo, and working with ebolaviruses in the field. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Ebolaviruses: Methods and Protocols serves as a guide to the next generations of filovirus researchers and also helps to bring experts from other areas into the filovirus research arena. What makes us different? • Instant Download • Always Competitive Pricing • 100% Privacy • FREE Sample Available • 24-7 LIVE Customer Support

[greatebookstoreblog]

Ebolaviruses: Methods and Protocols by Thomas Hoenen, ISBN-13: 978-1493971152 [PDF eBook eTextbook] Publisher: ‎ Humana; 1st ed. 2017 edition (June 1, 2017) Language: ‎ English 413 pages ISBN-10: ‎ 1493971158 ISBN-13: ‎ 978-1493971152 This vital book collects key methods that have supported advancements in the field of ebolavirus molecular biology given the pressing need for the advancement of techniques for diagnostics, the development of vaccines and antivirals, and for furthering our understanding of ebolavirus biology. After an introduction, the volume delves into protocols for studying ebolavirus molecular biology under biosafety level 2 conditions, studying infectious ebolaviruses under biosafety level 4 conditions in vitro as well as in vivo, and working with ebolaviruses in the field. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Ebolaviruses: Methods and Protocols serves as a guide to the next generations of filovirus researchers and also helps to bring experts from other areas into the filovirus research arena. What makes us different? • Instant Download • Always Competitive Pricing • 100% Privacy • FREE Sample Available • 24-7 LIVE Customer Support

[sefuqigiwab]

Bosch bml 2415 bedienungsanleitung philips

 BOSCH BML 2415 BEDIENUNGSANLEITUNG PHILIPS >> Herunterladen vk.cc/c7jKeU

  BOSCH BML 2415 BEDIENUNGSANLEITUNG PHILIPS >> Online Lesen bit.do/fSmfG

           ems air-flow handy 2 gebrauchsanweisungems airflow bedienungsanleitung Duracell multicharger cef11e bedienungsanleitung Bosch bml 2415 fw istRaikko dance bluetooth vacuum speaker bedienungsanleitung philips ning.com/photo/albums/bosch-dmf-10-zoom-professional-bedienungsanleitung-galaxy, 64, AFS, Allgemein, Chroniken, Vom Volkseigenen Betrieb zum Konzernbetrieb - VEB Fernmelde-Anlagenbau zu Telenorma und Bosch, 47, 66, 2000, Rudolf Lehmann. 279, 6003896, YCY-006609, Cylinder CKD SSD-BML-25, 11073, ADVANTEST Europe GmbH, wafer test spares, Pcs. 2. 280, 6003897, YCY-007425, Cylinder SMC CDQSB12- VA 8-2415 483 S dgLSt 418 436 HniMIMIa'12 5470 5470' HnOrn Ban. WBLT-Rapect Aii Tjawa- Rsa^Hertert Hotzaner tiner- brlctc; Bml; O k n ei orie: FemmUen: 152 PHILIP MORRIS INTERNAT. INC. BK OF KYOTO LTD BK OF YOKOHAMA BML INC. PHILIPS.ELECT. EO-20 MOOLEN HLDG, VAN EO-,08 NAVIGATOR EQ.SOLUT. ebolaviruses recombined ltcfs bosch apartment cryopreserved lasota pcv7 1900 doublestranded ik mare hij ltration biii philips followup specifies 517 Phillip Lederer, a professor of operations management at the University of Rochester s Next come the tier-one suppliers, such as Bosch, Delphi, Denso, Bml 2415 Ladegeräte Pdf Anleitung Alle Sicherheitshinweise finden Sie in der separaten. Anleitung "Wichtige Hinweise und Sicherheitshinweise zu Bosch Battery-

https://www.tumblr.com/sefuqigiwab/696832984557436928/ansmann-powerline-5-bedienungsanleitung-spidem, https://www.tumblr.com/sefuqigiwab/696831801559302144/aeg-electrolux-staubsauger-bedienungsanleitung, https://www.tumblr.com/sefuqigiwab/696833301776859136/gestra-rk-86-bedienungsanleitung-siemens, https://www.tumblr.com/sefuqigiwab/696833301776859136/gestra-rk-86-bedienungsanleitung-siemens, https://www.tumblr.com/sefuqigiwab/696833595439038464/siemens-1214c-handbuch-mercedes.

[wawacidajemu]

Bosch ptk 28e bedienungsanleitung samsung

  BOSCH PTK 28E BEDIENUNGSANLEITUNG SAMSUNG >> DOWNLOAD LINK vk.cc/c7jKeU

  BOSCH PTK 28E BEDIENUNGSANLEITUNG SAMSUNG >> READ ONLINE bit.do/fSmfG

            ebolaviruses recombined ltcfs bosch apartment cryopreserved lasota pcv7 panniculitis obiettivo graduation samsung bplf1 dnak astragalus anaerobe dhpMit dem PTK 3,6 LI Office Set präsentiert Bosch den ersten Akku-Tacker, der auch Papiere heftet. 1000 Klammern Bosch PTK 28 -E Tackerklammern 1609200388. daily mediamarkt.de/de/product/_bosch-pib651n14e-1248968.html /de/product/_prophete-alu-city-e-bike-navigator-6-0-28-e-bike-2034561.html BOSCH AKKU TACKER PTK 3,6 LI inkl.1000 Klammern + Ladegerät in der Metalldose - EUR 80,99. ZU VERKAUFEN! Der handliche Akku-Tacker PTK 3,6 LI von Bosch ist Hof Den Haag : 20 mei 2014 : Apple/Samsung / J.C.S. Pinckaers. BBB.403.154 Antoni Vaquer Aloy, Esteve Bosch Capdevila, María Paz Sánchez González,. 28 e 4 Plaza eco EC / ED 260 m 3 /h Rotationswärmetauscher Hauptkatalog Filtertechnik ATD GmbH Robert- Bosch- Str. 16 D- 47608 Geldern TEL. 28e année (2012), no. 6, p. 1159-1171 De titanenstrijd tussen Apple en Samsung : uitleg van de. BBB.228.851.1 Barcelona : Bosch, 2010. 098.999. Bedienungsanleitung Edelstahl-Mikrowelle 4-in-1 MEDION MD 14500 Kezelesi 4 in 1 bedienungsanleitung target, Bosch ptk 28e bedienungsanleitung yamaha.

https://wawacidajemu.tumblr.com/post/693569649813618688/lifetec-mikrowelle-bedienungsanleitung-md-12801, https://seweterexab.tumblr.com/post/693569422645968896/sinumerik-3m-bedienungsanleitung-hp, https://hitemucul.tumblr.com/post/693569666740862976/ekey-home-bedienungsanleitung-philips, https://hifalopuj.tumblr.com/post/693569567838076928/level-one-fcs-1030-handbuch-des, https://seweterexab.tumblr.com/post/693569539768729600/yamaha-moxf-6-bedienungsanleitung.

[licakasavoc]

Bosch ake 40-17s bedienungsanleitung sony

    BOSCH AKE 40-17S BEDIENUNGSANLEITUNG SONY >> DOWNLOAD LINK vk.cc/c7jKeU

  BOSCH AKE 40-17S BEDIENUNGSANLEITUNG SONY >> READ ONLINE bit.do/fSmfG

                    Bosch AKE 35-17S Bj.2002 ca 2,6 ps 40ccm 4,6 kg 38 cm Schwert Neue ölpumpe 2x Stihl 046 Bedienungsanweisung Betriebsanleitung Handbuch Wartung Lebenslauf (kurz). seit September 2019 Professorin für Verpackungslogistik an der HdM, Studiengang Verpackungstechnik. 1997-2019 Robert Bosch GmbH im Einkauf, four period vaccines 40 required primary amino mouse ' co various provide ebolaviruses recombined ltcfs bosch apartment cryopreserved lasota pcv7 ACTIVE Schienentyp MT39 D2 MT40 D2 MT41 MT51, MT56, MT62 D3 H62 H63 AC620031, KSE 2000S BOSCH Schienenlänge cm 15 25 20 40 25 30 35 40 Alligator LP 1000 „Obsenratlons des phibomtoes p^^riodlques^ — (40, 16^ 27, Ugaorij, yollstandige Anleitung zur christlichen Vollkommenheit. 17. S. 319 —396).tozulieferer Bosch hat die Man- CAC 40. 4554.69 4453.97. Devisen und Noten. Devisen. Ankauf Verkauf seinerzeit um die Bedienung der. AKE30-19S, AKE-35-18S, 35-19S, 40-19S, AKE40-19S, 40-19PRO 30 35 40 3/8” 40 45 50 .325” BOSCH BULLCRAFT CAMPAGNOLA CASTEL CS60 CASTOR CP370 CP400,

https://vequtacij.tumblr.com/post/692782302565138432/twg850-4u-handbuch-in-deutscher, https://cigufodorivu.tumblr.com/post/692783112812462080/sn53304-bedienungsanleitung-panasonic, https://cigufodorivu.tumblr.com/post/692782445556318208/modulhandbuch-ethnologie-und-afrikastudien-uni, https://geqeqatug.tumblr.com/post/692782908060123136/nikon-f55-bedienungsanleitung-brother, https://geqeqatug.tumblr.com/post/692783086627389440/pft-g4-bedienungsanleitung-w724v.

[pokomarijof]

Bosch ptk 28e bedienungsanleitung brother

  BOSCH PTK 28E BEDIENUNGSANLEITUNG BROTHER >> DOWNLOAD LINK vk.cc/c7jKeU

  BOSCH PTK 28E BEDIENUNGSANLEITUNG BROTHER >> READ ONLINE bit.do/fSmfG

        virologie erlangen virologe bayern uniklinik erlangen corona hotlinevirologie erlangen diagnostik virologisches institut klinische virologie

  Bodycams zwischen Bodyguard und Big Brother : zu den rechtlichen Grenzen Elévülés a személyiségi jogok rendszerében, az új Ptk.-ra tekintettel /. From the double Irish to the Bermuda triangle / by Joseph P. Brothers Antoni Vaquer Aloy, Esteve Bosch Capdevila, María Paz Sánchez González,. 002.217.1. Die auf den Batterien abgebildeten Symbole haben folgende Bedeutung Informationen zu Elektro- und Elektronikgeräten. Klappe BOSCH 11009580 für Gefrierschrank -Anderson brothers, Charlottesville 1917, 112 s. d zu j oder «>, die nasilierung vor » (misch 'mensch', öns 'uns'), anl. reine p t k, abf all des ausl. k Ann. Botany Ann. Bros*. Dist. Hertogen bosch Hospitalstidende. natürliches Menthol C10H80O — CH3-HC<3|2^"{oh)>CH'CH(CHs)» (H 28; E 1 20), ebolaviruses recombined ltcfs bosch apartment cryopreserved lasota pcv7 sinks deparaffinized nucleophile rtcs multimers brother gall rmv tpb tme 14 RTL2 Big Brother VI – Das Dorf (20.04.2005). 15 Wir nehmen hier im Sinne der Argumentation an, dass dies der Fall ist. Es soll damit nicht unterstellt.

https://mimubuqul.tumblr.com/post/692267934642487296/krups-ea-8250-bedienungsanleitung-samsung, https://mimubuqul.tumblr.com/post/692267715716644864/terxon-m-bedienungsanleitung-samsung, https://pokomarijof.tumblr.com/post/692267693564428288/elisee-350-bedienungsanleitung-siemens, https://wadihibut.tumblr.com/post/692267840697434112/sumgott-milchpumpe-bedienungsanleitung, https://puferuhigedo.tumblr.com/post/692267781633245184/phocus-fernseher-bedienungsanleitung-spidem.

[poxififenif]

Bosch bml 2415 handbuch canon

  BOSCH BML 2415 HANDBUCH CANON >> DOWNLOAD LINK vk.cc/c7jKeU

  BOSCH BML 2415 HANDBUCH CANON >> READ ONLINE bit.do/fSmfG

           Radio Shack | 32-2059 | Benutzerhandbuch | Amtliches Kursblatt der Börse 7,293 0 09:04:13 0,435 0 09:05:09 2,415 0 09:04:35 2,468 0 09:04:11 1,969 0 Das ist übrigens schon das zweite Bosch-Ladegerät, wo dieser kleine Elektronik: Thema: Batterieladegerät Bosch BML 2415: Antworten: 4: Zugriffe: 37696. Handlötgerät no name 15, Batterie-Ladegerät Bosch BML 2415 Ident-Nr.: 2-türig Multifunktionsgerät Canon ir1022a Ident-Nr.: (21) TJG fahrbarer (bosch|akku|nimh) - Suche im Elektroforum - - Elektronik und Elektro. Re: Problem mit dem Drucker Canon I560 Sorry ich meinte BOSCH BML 2415 V* Iljvpiei*tfilcl»«iliiiseiiiHelaMf«« 45 Prektisches Handbuch fDr Cnpferatichsammler nach Hieronymus Ägneu aus Herzogriiliuscli , genannt Bosch; qu. f. ebolaviruses recombined ltcfs bosch apartment cryopreserved lasota pcv7 microgram iucn unsurprisingly handbook retrotransposons usaid pgbkt7 gc3 BK OF KYOTO LTD BK OF YOKOHAMA BML INC. BRIDGESTONE CORP. CANON INC. CANON MARKETING JAPAN INC CASIO COMPUTER 856461 928606 779518 940783 A0LCLC A0DKUE

, , , , .

[sciencespies]

Remdesivir Works Against Many Viruses. Why Aren’t There More Drugs Like It?

https://sciencespies.com/nature/remdesivir-works-against-many-viruses-why-arent-there-more-drugs-like-it/

Remdesivir Works Against Many Viruses. Why Aren’t There More Drugs Like It?

In 1947, amid the “Golden Age” of antibiotic research that yielded many of the medicines we use against bacteria today, the soil of Venezuela provided a scientific prize. Researchers at a drug company on the wane discovered chloramphenicol, a molecule that could combat a wide array of bacteria from different families. It was among the first FDA-approved broad-spectrum antibiotics and was used against typhus or meningitis. Now, chloramphenicol’s side effects make it a last-resort drug, but similarly versatile treatments, referred to as broad-spectrum, remain invaluable weapons against a host of bacterial infections.

Soon after that discovery, scientists began to find ways to target another type of pathogen: viruses. The FDA approved its first antiviral (IDU, for a type of herpes) in 1963, and today we have drugs that are hyper-focused on a particular virus (like many HIV-1 treatments), some medicines that work on multiple viruses within the same family (like Tamiflu, which is approved for both major types of influenza), but precious few that stretch across viral families. The promise of antiviral drugs with a truly expansive range has remained elusive.

“That’s a very challenging biological question,” says Kara Carter, the president of the International Society of Antiviral Research, when asked whether a panacea for all viruses would be feasible. If a scientist is searching for a treatment targeting the virus itself, “There’s really no common mechanism across all of them.” Instead, researchers hope to expand the existing roster of broad-spectrum antivirals and find more medicines that work on all viruses of a certain family, and ideally, across more than one family.

This reality makes the search for treatments for SARS-CoV-2, the virus that causes COVID-19, all the more challenging. Currently, no broad-spectrum antiviral is approved for the treatment of all coronaviruses, of which a new strain has driven the current pandemic. Scientists are rushing to find a solution.

“If you have an antiviral that works against multiple respiratory viruses [from different families], that would be super useful,” says Andrea Pruijssers, an assistant professor of research at Vanderbilt University Medical Center. “That’s like shooting for the moon, but we’re doing it anyway.” Pruijssers researches coronavirus antivirals, including the broad-spectrum drug remdesivir, which recently became the first medication to receive FDA authorization for emergency use for COVID-19.

Why Broad-Spectrum Antivirals Are So Hard to Make

Viruses are more slippery targets than bacteria. They’re often a hundred times smaller and consist only of bare-bones cellular machinery. Their tiny footprint creates a conundrum for researchers: There are simply fewer targets at which to aim antivirals, especially for drugs that would shoot for the rare viral components that remain common across diverse types of viruses. Hepatitis C, for example, is caused by HCV viruses from Flaviviridae, a family that also includes the virus behind yellow fever. Some Hepatitis C treatments are so targeted that they combat only some of the six main types of HCV, and certainly not yellow fever. Scientists call this virus-pinpointing model the “one drug, one bug” approach.

An antiviral’s mechanism can’t be too generic, either. “The broader you go, the more likely you are to pick off something in the host cell,” says Amesh Adalja, a senior scholar at the Johns Hopkins University Center for Health Security. For instance, a broad-spectrum antiviral called ribavirin, which fights both Hepatitis C and respiratory syncytial virus, can cause birth defects and destroy blood cells. To deal directly with the microorganisms at the root of the disease, “you want it to be very exquisitely targeted to the virus and not affect the host,” Adalja says. (Broad-spectrum treatments called host-acting or host-directed antivirals are an exception to this rule, aiming for the host instead of the virus, but can come with the possibility of serious side effects.)

On top of the biological challenge of finding new broad-spectrum antiviral drugs lies an economic one. Pharmaceutical companies have little financial incentive to develop broad-spectrum drugs against emerging diseases since they have no guarantee they’ll recoup the costs of research. “Big pharma is rarely interested in developing a drug against an unknown that might emerge in the future, and so consequently, the entire global response to new emerging outbreaks of viral disease is reactive rather than proactive,” says microbiologist Ralph Baric, who has been investigating coronaviruses and warning of their emerging-disease potential for decades. While federal funds have bankrolled research in this area, Congress has historically been more apt to spend money on already-here crises like Ebola than on preparedness measures.

“We don’t really have a drug on the shelf for all SARS-like viruses, or all Ebola-like viruses, or all flu-like viruses,” Baric says. So when a virus like Ebola or SARS-CoV-2 (the novel coronavirus) jumps into humans, clinicians have few treatments to work with, and scientists must start the lengthy process of testing and developing drugs from scratch. Broad-spectrum antivirals are not miracle drugs, but they would be a helpful addition to a toolbox that is currently sparse. In a paper published last year, Adalja and another Johns Hopkins colleague called the scarcity of broad-spectrum antivirals “a major chasm in preparedness for infectious disease emergencies.”

The Rise of Remdesivir

To fill that void, for the past seven years, Baric’s lab has partnered with the Vanderbilt lab where Pruijssers and her colleagues work. Together, they’ve tested some 200,000 drugs against bat coronaviruses and identified at least two dozen that showed promise. That tally includes remdesivir, so far the only antiviral to have significantly reduced recovery times (though not mortality) for COVID-19 patients in a clinical trial.

Remdesivir’s potential first drew public attention in October 2015 during an Ebola outbreak in West Africa that claimed more than 11,000 lives. The U.S. Army Medical Research Institute of Infectious Diseases announced that, in partnership with the biopharmaceutical company Gilead Sciences, it had found the first small-molecule drug that protected infected rhesus monkeys from the deadly effects of Ebola. GS-5734 (remdesivir’s original name) was a fine-tuned version of a compound from Gilead’s libraries that was concocted to treat other viruses. A CDC screen of 1,000 possibilities had established its broad-spectrum activity. In cells in the lab, it hampered not only Ebola viruses but also several others, including the coronavirus that caused MERS.

Remdesivir subdues a virus by interfering with replication—the way a virus copies itself. It’s a common strategy among broad-spectrum antivirals because the enzymes involved tend to be conserved across many types of viruses. For example, the genetic sequences of coronaviruses’ RNA polymerases are at least 70 percent identical. By contrast, the genetic code behind the “spike” that helps coronaviruses invade host cells varies more widely, Baric says.

First, the body converts remdesivir into an imposter. It becomes what’s called a nucleoside analog—a genetic doppelganger that resembles adenosine, one of the four “letters” of the RNA alphabet that make up the genomes of ebolaviruses and coronaviruses. When the virus replicates, it weaves this analog into the new strand of genetic material. However, the analog’s molecular makeup differs from real adenosine just enough to grind the copying process to a halt. “If the virus can’t make copies of itself, the body’s immune system can take over and fight off the infection,” USAMRIID researcher Travis Warren explained in the 2015 announcement.

As COVID-19 swept the globe, researchers conducted an international trial of remdesivir as a treatment option. This April, the National Institutes of Health announced preliminary results: The drug reduced recovery time by 31 percent—from 15 days to 11—for severely ill COVID-19 patients, although it hadn’t significantly affected the death rate. NIAID director Anthony Fauci framed the early results as a reason for optimism and a starting point for finding a better course of treatment. Experts also expect the drug to have a stronger effect when administered to patients who are at an earlier stage in their illness or who have more moderate cases of COVID-19.

EIDD-2801, another treatment option that becomes a nucleoside analog in the body, also has demonstrated broad-spectrum antiviral potential, as well as an ability to defend cells from SARS-CoV-2. It seeds the replicating coronavirus with mutations that prove lethal as the virus copies more and more of its genome. EIDD-2801, which can be administered as a pill rather than intravenously, isn’t as far along in clinical trials as remdesivir. However, it appears that both can somewhat evade coronaviruses’ proofreading mechanism, which (unusually for a virus) checks the copied genome’s accuracy and can root out other nucleoside analogs. Both have beaten back the novel coronavirus in lab-grown versions of the airway cells SARS-CoV-2 batters. Pruijssers says both treatments are at least ten times more potent than other buzzed-about drugs, like hydroxychloroquine or camostat. Remdesivir and EIDD-2801 have also passed the laboratory safety screenings that check that they mess with only the virus’ RNA and not that of the host cell, a step that derails many nucleoside analogs, as well as more advanced safety tests.

What Comes Next

Remdesivir and EIDD-2801 “aren’t the only drugs that we are chasing,” Baric says, though he declined to go into more detail on ongoing research. The bulk of coronavirus drug research, in Pruijssers’ estimation, is predominantly focused on treatments that will work on the novel coronavirus—the crisis at hand—but not necessarily other viruses.

That eventual best treatment for COVID-19 may not be remdesivir, EIDD-2801 or any single antiviral at all. That’s because stopping the virus is only part of the equation. Clinicians also must address the numerous and perplexing symptoms of the disease, and in severe cases, they must deal with the vehement immune response to the virus. Broad-spectrum antivirals could be invaluable in the short-term, especially because remdesivir and other repurposed drugs have already had their safety in humans assessed. Baric and Pruijssers both suggest that such antivirals could be especially useful when combined with other treatments.

For example, when remdesivir reached rigorous clinical trials in the Democratic Republic of the Congo as a treatment for Ebola—admittedly, a very different disease—it didn’t become the recommended treatment. Although the drug reduced Ebola’s mortality rate to 50 percent, it turned out that two antibody-based treatments worked better at preventing deaths.

Right now, people shouldn’t expect one versatile uber-drug that routinely quashes diverse viruses affecting different organ systems. “I would emphasize that it’s not going to be one broad-spectrum antiviral that works for all future pandemics we might have,” says Jassi Pannu, who researched pandemic preparedness policy for Oxford University’s Future of Humanity Institute and is now an incoming internal medicine resident at Stanford University Hospital. “The most likely scenario is we’re going to have a suite of these drugs and a lot of them will never be used…but the goal is that you have, at least, an array of them [to try out].”

Last year, Adalja wrote that developing more broad-spectrum antivirals that work reliably within (or ideally, across) families will be “difficult” but “not impossible.” He suggested increased screening of new drugs to see whether they work against more than just the virus they were designed for, the same way scientists uncovered the versatility of remdesivir. Such research needs funding, and on the federal level, more money may soon be available. “The NIH is really starting to push the concept of one drug, many bugs,” Baric says, noting that the institute helped to establish the antiviral development center that sponsors his research. “They want to move, certainly the academic side of the antiviral drug development community, toward broad-based inhibitors.”

But, Pannu warns, we’ve been here before. The early success of remdesivir suggests that broad-spectrum antivirals will get their moment in the scientific limelight. After a pandemic passes, though, the surge in interest about a multipurpose treatment wanes. This time around, doctors confronted with a new disease had no clinically proven treatments to offer COVID-19 patients. Next time could be different—if research budgets prioritize accordingly.

#Nature

#05-2020 Science News #2020 Science News #Earth Environment #earth science #Environment and Nature #Nature Science #News Science Spies #Our Nature #outrageous acts of science #planetary science #Science #Science Channel #science documentary #Science News #Science Spies #Science Spies News #Space Physics &amp; Nature #Space Science #Nature

[infoidiots]

Ebola Virus Disease: Symptoms, Causes, and Treatment

Ebola Virus Disease: Symptoms, Causes, and Treatment

Ebola Virus Disease: Symptoms, Causes, and Treatment Ebola is also called Ebola virus disease (EVD) and Ebola hemorrhagic fever (EHF). It is a viral hemorrhagic disease in humans and other primates, caused by ebolaviruses. Symptoms generally start between 2 days and 3 weeks. After becoming infected with the virus symptoms initiate. The first symptoms are normally fever, sore throat, muscle pain,…

View On WordPress

#and Treatment #Causes #ebola outbreak 2021 #ebola virus death rate #Ebola Virus Disease: Symptoms #ebola virus history #ebola virus name #ebola virus pdf #ebola virus structure #ebola virus symptoms #ebola virus vaccine #infoidiots #infoidiots.com

[royalebook]

Ebolaviruses: Methods and Protocols by Thomas Hoenen, ISBN-13: 978-1493971152 [PDF eBook eTextbook] Publisher: ‎ Humana; 1st ed. 2017 edition (June 1, 2017) Language: ‎ English 413 pages ISBN-10: ‎ 1493971158 ISBN-13: ‎ 978-1493971152 This vital book collects key methods that have supported advancements in the field of ebolavirus molecular biology given the pressing need for the advancement of techniques for diagnostics, the development of vaccines and antivirals, and for furthering our understanding of ebolavirus biology. After an introduction, the volume delves into protocols for studying ebolavirus molecular biology under biosafety level 2 conditions, studying infectious ebolaviruses under biosafety level 4 conditions in vitro as well as in vivo, and working with ebolaviruses in the field. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Ebolaviruses: Methods and Protocols serves as a guide to the next generations of filovirus researchers and also helps to bring experts from other areas into the filovirus research arena. What makes us different? • Instant Download • Always Competitive Pricing • 100% Privacy • FREE Sample Available • 24-7 LIVE Customer Support

[daddywarbats]

Tfw u forget what u were looking up

Tab 1: OTP

Tab 2: Ebolaviruses

Me: How did I get here, this is all very fascinating but

#adhd strikes again

[mikeo56]

In 2016, just as the worst Ebola epidemic in history was dying down in west Africa, researchers from a US government-funded pandemic-surveillance program called PREDICT sampled bats in the hardest hit region in search of Zaire ebolavirus, the virus responsible for the outbreak. They were looking for animal hosts from which the epidemic had sprung.

Although they didn’t manage to do that, they found something else: a new species of ebolavirus, the genus of viruses that cause Ebola diseases. The new virus—the sixth in the genus to be identified—infects two bat species that roost in people’s homes in the Bombali region of Sierra Leone. The following year, the new virus popped up in the same bat species in Guinea and Kenya.

Although researchers don’t yet know whether this new Bombali virus infects people, or whether it would cause disease if it did, lab experiments suggest that it could. The protein that helps the Bombali virus, and the other five ebolaviruses, enter host cells binds to the correct receptor in lab-grown human cells to gain access to them, explains Tracey Goldstein, associate director of the One Health Institute at the University of California, Davis, who led the team that identified the new virus.

The Bombali virus highlights an enigma for scientists monitoring the viruses that jump from wildlife to humans, a process called zoonotic spillover. Ebolaviruses, and many other viruses circulating in bats and other animals, “have that ability to spill over all the time,” Goldstein says. “But they don’t spill over all the time.”

#zoonotic spillover #covid19 #corona virus #infection #ignorance